Why Praxis Precision Medicines, Inc. (PRAX) stock moved
Praxis Precision Medicines, Inc. (PRAX) shares climbed 16.0% to $370.16 as of August 7, 2026, a sharp gain from the prior close of $319.23. BestStocks flagged the session as a major change for PRAX. The move is tied to price move up. Below, we break down what changed for PRAX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
PRAX climbed 16.0% to $370.16
PRAX climbed 16.0% in its latest session, moving from $319.23 to $370.16.
What it means for Praxis Precision Medicines, Inc. investors
For Praxis Precision Medicines, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 16.0% price move with conviction. Weighing against that: Praxis Precision Medicines, Inc. (PRAX) moved -3.17% from $314.41 to $304.43 on 2026-07-20; Praxis Precision Medicines, Inc. (PRAX) moved −3.21% from $318.42 to $308.20 on 2026-07-16. Wall Street's consensus price target sits at $578.86, implying +56.4% upside from $370.16. BestStocks rates the overall signal quality medium (74/100). With earnings roughly 96 days out, the next report is the most likely near-term test of the move.
PRAX price reaction
PRAX last traded at $370.16, up $50.93 (+15.95%) from the previous close of $319.23. The session traded on 2.9× average volume (very high), so the move carried above-average conviction. Over the past month the stock has ranged between $291.03 and $370.16, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Praxis Precision Medicines, Inc. (PRAX)
The consensus analyst price target on Praxis Precision Medicines, Inc. (PRAX) is $578.86, 56.4% above the recent $370.16. Over the past 90 days analysts logged 0 upgrades, 12 maintains, and 0 downgrades. Here is how the bullish and bearish cases on PRAX line up.
The bullish case
- Wall Street's consensus price target of $578.86 implies +56.4% upside from $370.16.
- The Street's most bullish target is $1,201.00 (+224.5%).
- Material positive event.
- Strong 16.0% price move with conviction.
- Volume 2.9x average — institutional conviction.
The bearish case
- The most bearish analyst target is $162.00 (-56.2%).
- Praxis Precision Medicines, Inc. (PRAX) moved -3.17% from $314.41 to $304.43 on 2026-07-20.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 6, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for PRAX
Frequently asked questions about PRAX
Why did Praxis Precision Medicines, Inc. (PRAX) stock move?
PRAX climbed 16.0% to $370.16. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did PRAX stock rise?
PRAX gained 15.95% ($50.93) versus the prior close of $319.23, last trading at $370.16 on 2.9× average volume.
When is Praxis Precision Medicines, Inc.'s next earnings date?
PRAX's next earnings report is estimated for 2026-11-11 — about 96 days away.
What is the analyst price target for PRAX?
The consensus analyst price target for PRAX is $578.86, about 56.4% above the current $370.16. Over the past 90 days, analysts recorded 0 upgrades, 12 maintains, and 0 downgrades.
How BestStocks tracks PRAX
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 18 tracked change events for PRAX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 7, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.